Delmetacin

Delmetacin

SCHEMBL286727

Cc1c(CC(=O)O)c2ccccc2n1C(=O)c1ccccc1

nearest known ligand 0.82

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 5/20 0.82
PTGS1 P23219 3/20 0.82
PTGS2 P35354 3/20 0.82
LMNA P02545 2/20 0.69
CYP1A2 P05177 2/20 0.69
CYP2D6 P10635 2/20 0.69
CYP2C9 P11712 2/20 0.69
HIF1A Q16665 2/20 0.69
NPSR1 Q6W5P4 2/20 0.69
TSHR P16473 1/20 0.69
NFKB1 P19838 1/20 0.69
AKR1C3 P42330 7/20 0.60
AKR1C2 P52895 7/20 0.60
PLA2G2A P14555 1/20 0.56
PTGIR P43119 1/20 0.55
PTGDR2 Q9Y5Y4 2/20 0.55
AKR1C4 P17516 2/20 0.55
AKR1C1 Q04828 2/20 0.55
KDM4E B2RXH2 1/20 0.55
MEN1 O00255 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13802409 0.93 ABCB1 (0.81) ABCB1PTGS1PTGS2LMNACYP1A2
SCHEMBL6206650 0.92 ABCB1 (0.79) ABCB1PTGS1PTGS2LMNACYP1A2
SCHEMBL2237296 0.91 ABCB1 (1.00) ABCB1PTGS1PTGS2LMNACYP1A2
SCHEMBL6206463 0.91 ABCB1 (0.77) ABCB1PTGS1PTGS2LMNACYP1A2
SCHEMBL13802410 0.90 ABCB1 (0.68) ABCB1PTGS1PTGS2LMNACYP1A2
SCHEMBL12571248 0.89 ABCB1 (0.70) ABCB1PTGS1PTGS2LMNACYP1A2
SCHEMBL2237310 0.89 PLA2G2A (0.70) ABCB1PTGS1PTGS2LMNACYP1A2
SCHEMBL13802380 0.88 AKR1C3 (0.78) ABCB1PTGS1PTGS2LMNACYP1A2
SCHEMBL4211502 0.87 ABCB1 (0.76) ABCB1PTGS1PTGS2LMNACYP1A2
SCHEMBL13802387 0.87 ABCB1 (0.72) ABCB1PTGS1PTGS2LMNACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 605 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116348100-A Use of AKR1C3 activated compounds 深圳艾欣达伟医药科技有限公司 2023-06-27 CN claimed
EP-1590314-B1 2-ARYL-ACETIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DOMPÉ FARMACEUTICI S P A (IT) 2015-08-05 EP claimed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US claimed
US-8871784-B2 2-aryl-acetic acids, their derivatives and pharmaceutical compositions containing them DOMPE'S.P.A. (IT) 2014-10-28 US claimed
US-20120183600-A1 NOVEL COMPOSITION FOR TREATING METABOLIC SYNDROME AND OTHER CONDITIONS CHEN CHIEN-HUNG (US) 2012-07-19 US claimed
US-20100267726-A1 2-ARYL-ACETIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DOMPE PHA.R.MA S.P.A. (IT) 2010-10-21 US claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 US claimed
CN-101330905-A Freeze-drying process and products obtained thereby SCIDOSE LLC (US) 2008-12-24 CN claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 US claimed
US-20060223842-A1 such as (5-acetyl-1-methyl-1H-pyrrol-2-yl)acetyl methanesulphonamide, used for the of treatment of psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), skin disorders, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and reperfusion injuries after ischemia DOMPÉ FARMACEUTICI S.P.A. (IT) 2006-10-05 US claimed
EP-1590314-A2 2-ARYL-ACETIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Dompe' S.P.A. (IT) 2005-11-02 EP claimed
WO-2004069782-A2 2-ARYL-ACETIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DOMPE' S.P.A. (IT) 2004-08-19 WO claimed
EP-1336602-A1 Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases Scaramuzzino, Giovanni (IT) 2003-08-20 EP claimed
US-20250304667-A1 COMPLEMENT COMPONENT C5 ANTIBODIES ALLERGAN INC (US) 2025-10-02 US disclosed
US-20240294652-A1 IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS AMGEN K-A, INC. 2024-09-05 US disclosed
EP-0138481-A2 Leukotriene biosynthesis inhibitors MERCK FROSST CANADA INC. (CA) 1985-04-24 EP disclosed
EP-0136893-A2 Benzo[a]phenothiazines and hydro-derivatives and pharmaceutical compositions containing them MERCK FROSST CANADA INC. (CA) 1985-04-10 EP disclosed
EP-0123541-A1 Leukotriene antagonists MERCK FROSST CANADA INC. (CA) 1984-10-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267726-A1 2-ARYL-ACETIC ACIDS, THEIR DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM CXCR2, MMP8, CXCR1 ABCB1 3451/4885PTGS1 128/4885PTGS2 124/4885
US-20060223842-A1 such as (5-acetyl-1-methyl-1H-pyrrol-2-yl)acetyl methanesulphonamide, used for the of treatment of psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), skin disorders, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and reperfusion injuries after ischemia CXCR2, CXCR1, MMP8 ABCB1 4043/4885PTGS1 52/4885PTGS2 121/4885
US-20240294652-A1 IL-17 RECEPTOR A ANTIGEN BINDING PROTEINS IL17A, IL23R, IL15RA ABCB1 3722/4885PTGS1 3044/4885PTGS2 3854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.